Sanofi’s Insulin Toujeo® now available for treatment of adults with diabetes in UK
Sanofi has announced today that Toujeo® (insulin glargine [rDNA origin] 300 units/mL), a long-acting, once-daily basal insulin treatment is available for clinicians to prescribe in the UK.
The drug has demonstrated similar glycaemic control with a lower incidence of confirmed hypoglycaemia when compared to Lantus® in the treatment of adults with type 2 diabetes.
It provides another option for adults with type 1 and type 2 diabetes to help manage their condition. Insulin glargine 300 units/ml is indicated for the treatment of diabetes mellitus in adults and is a novel formulation of the glargine molecule Lantus® (insulin glargine 100 units/mL) currently used in the treatment of diabetes.
Over two thirds of adults treated with insulin do not reach the National Institute for Health and Care Excellence (NICE) target for blood glucose control (HbA1c ≤ 7.5 per cent), increasing their risk of potentially avoidable complications such as amputation, blindness and renal disease.
Many clinicians cite concern of hypoglycaemia as a reason for not managing blood glucose more aggressively – three quarters (75.5 per cent) of specialists would be more aggressive in treating diabetes if there was no concern about hypoglycaemia. For people with diabetes, concern over hypoglycaemia may cause them to modify their insulin dose – four out of ten people with type 2 diabetes reduce their insulin dose after an episode of mild hypoglycaemia and six out of ten after a severe hypoglycaemic episode.
This new basal insulin is an additional treatment option for doctors to help manage patients who are not currently able to reach optimal glycaemic control
Melanie Davies, Professor of Diabetes Medicine, University of Leicester and Honorary Consultant, University Hospitals Leicester, said: “This new basal insulin is an additional treatment option for doctors to help manage patients who are not currently able to reach optimal glycaemic control.
“Hypoglycaemia is one of the most frequent adverse events experienced by people treated with insulin and fear of these events can prevent some patients administering appropriate insulin doses and can even lead to discontinuation of treatment. The consequence may be poor blood glucose control and an increased risk of long-term complications.”
Results from clinical trials evaluating the efficacy and tolerability of insulin glargine 300 units/mL compared to insulin glargine 100 units/mL demonstrated a similar blood glucose (HbA1c) reduction with a lower incidence of confirmed hypoglycaemia in patients with type 2 diabetes on insulin glargine 300 units/mL compared to those on insulin glargine 100 units/ml.
In people with type 1 diabetes, trials demonstrated similar blood glucose (HbA1c) reduction but showed no difference in confirmed hypoglycaemia. Insulin glargine 300 units/mL also showed a more stable and more prolonged glucose lowering effect that lasted beyond 24 hours, and low within-individual blood- sugar variability.
Dr David Williams, Medical Director for Sanofi UK, said: “The availability of Toujeo in the UK is a significant milestone for Sanofi as we expand our portfolio of medicines for patients with both type 1 and type 2 diabetes and reinforces our commitment to continue improving the quality of diabetes care.”
Insulin glargine 300 units/mL was licensed by the European Medicines Agency (EMA) in February 2015. It has also been licensed by the U.S. Food and Drug Administration (FDA) and is under review by other regulatory authorities around the world.
Insulin glargine 300 units/mL forms a compact subcutaneous depot with a reduced surface area8,9 and allows for a slower, more prolonged release of insulin glargine beyond 24 hours. Insulin glargine 300 units/mL and insulin glargine 100 units/mL are not bioequivalent and therefore are not interchangeable. Switching from once-daily insulin glargine 300 units/mL, to insulin glargine 100 units/mL results in an increased risk of hypoglycaemic events, mainly in the first week after the switch. To reduce this risk, patients should reduce their dose by 20 per cent. When switching to or from insulin glargine 300 units/mL, close metabolic monitoring is recommended during the transition and in the initial weeks thereafter.